Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Lacosamide Extension in Partial-onset Seizures
NCT00530855Phase 3Completed
- Sponsor
- UCB
- Start
- Feb 2008
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of lacosamide in focal onset seizure, sponsored by UCB. Primary endpoints: Percentage of Subjects on Lacosamide (LCM) Monotherapy at Any Time Between Visit 1 and End of Study at 2 years and Duration of Lacosamide (LCM) Monotherapy Treatment From Visit 1 to End of Study at 2 years. Started Feb 2008; status: completed.
02
Drugs
lacosamide
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT00530855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00530855.